Loading...
•
Sep 30, 2022
Dynavax Q3 2022 Earnings Report
Reported financial results for the quarter ended September 30, 2022.
Key Takeaways
Dynavax reported a successful Q3 2022 with a 55% increase in total revenue compared to Q3 2021, driven by strong performance of HEPLISAV-B and CpG 1018 adjuvant. The company is on track for a second consecutive year of profitability.
Total revenue reached $167.7 million, a 55% increase from Q3 2021.
HEPLISAV-B vaccine net product revenue was $37.5 million, up 65% compared to Q3 2021.
CpG 1018 adjuvant net product revenue was $126.3 million, a 50% increase from Q3 2021.
The company reiterates its guidance for full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million.
Revenue by Segment
Forward Guidance
Dynavax anticipates 2022 revenues, operating expenses, and other costs to be consistent with the Company’s previous financial guidance provided on August 4, 2022.
Positive Outlook
- Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million
- Associated gross margin anticipated to be approximately 60%
- Research and development expenses to be between approximately $50-$60 million
- Selling, general and administrative expenses to be between approximately $130-$140 million
- Interest expense of approximately $7 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...